<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03317366</url>
  </required_header>
  <id_info>
    <org_study_id>ARQ 092 Expanded Access</org_study_id>
    <nct_id>NCT03317366</nct_id>
  </id_info>
  <brief_title>Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies</brief_title>
  <official_title>Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies With Genetic Alterations of the PI3K/AKT Pathway</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck &amp; Co., Inc.)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck &amp; Co., Inc.)</source>
  <brief_summary>
    <textblock>
      ARQ 092 is being investigated for patients with overgrowth diseases and/or vascular anomalies&#xD;
      with genetic alterations of the PI3K/AKT pathway and may be available for patients who are&#xD;
      ineligible for an ongoing ARQ 092 clinical trial or have other considerations that prevent&#xD;
      access to ARQ 092 through an existing clinical trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Proteus Syndrome</condition>
  <condition>PIK3CA-Related Overgrowth Spectrum (PROS)</condition>
  <condition>Growth Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARQ 092</intervention_name>
    <description>Open-label expanded access for ARQ 092 capsules</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Severe overgrowth diseases and/or vascular anomalies with confirmed somatic genetic&#xD;
             alterations of PIK3CA or AKT&#xD;
&#xD;
          2. Are unable to participate in an ongoing ARQ 092 clinical trial&#xD;
&#xD;
          3. Willing and able to provide written, signed informed consent. In the case of a minor,&#xD;
             a parent or legal guardian must sign an informed consent form.&#xD;
&#xD;
          4. Medically suitable for treatment with ARQ 092&#xD;
&#xD;
          5. Not eligible for any other available therapy for the diagnosed overgrowth disease&#xD;
             and/or vascular anomaly with confirmed somatic genetic alterations of PIK3CA or AKT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Currently enrolled in an ongoing clinical study of ARQ 092 or other investigational&#xD;
             drug&#xD;
&#xD;
          2. Currently being treated with any inhibitor of the PI3K/AKT/mTOR pathway&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 17, 2017</study_first_submitted>
  <study_first_submitted_qc>October 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2017</study_first_posted>
  <last_update_submitted>July 31, 2021</last_update_submitted>
  <last_update_submitted_qc>July 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ARQ 092</keyword>
  <keyword>ArQule</keyword>
  <keyword>AKT</keyword>
  <keyword>PIK3CA</keyword>
  <keyword>Overgrowth</keyword>
  <keyword>Congenital malformations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proteus Syndrome</mesh_term>
    <mesh_term>Vascular Malformations</mesh_term>
    <mesh_term>Growth Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

